Oramed Pharmaceuticals Inc.

Name: Oramed Pharmaceuticals Inc. standardized financial statements, quarterly
Creator: Listed

ORMPNasdaqCIK 1176309HealthcareFiscal year ends Dec 31

Share this page

Link

Story card, 1080 × 1920

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$0, Q4 FY2025

Operating income−$2.8m, Q2 FY2026

Net income$78.2m, Q2 FY2026

Oramed Pharmaceuticals Inc., income statement, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Revenue	$m	0.0	0.0	not reported	not reported	not reported	not reported	2.0	0.0	0.0	0.0	not reported	not reported
Cost of revenue	$m	not reported	not reported	not reported	not reported	not reported	not reported	2.0	0.0	0.0	0.0	not reported	not reported
Gross profit	$m	not reported	not reported	not reported	not reported	not reported	not reported	0.0	0.0	0.0	0.0	not reported	not reported
Research and development	$m	1.0	1.8	1.2	1.4	2.2	1.5	2.2	1.0	1.2	2.0	1.6	0.0
Operating income	$m	(2.9)	(3.9)	(3.0)	(3.1)	(3.1)	(3.6)	(4.5)	(2.5)	(2.4)	(5.7)	(3.7)	(2.8)
Interest expense	$m	0.8	1.2	0.6	0.3	0.0	0.0	not reported	not reported	not reported	not reported	not reported	not reported
Income tax	$m	not reported	not reported	not reported	1.6	1.1	0.4	0.6	(0.1)	11.1	(0.2)	11.1	23.4
Net income	$m	(3.2)	12.9	1.5	9.2	(19.6)	(10.2)	(7.6)	13.3	48.4	10.0	38.3	78.2
Diluted EPS	$ per share	(0.08)	not reported	0.04	0.22	(0.48)	not reported	(0.19)	0.31	1.13	not reported	0.91	1.84
Basic EPS	$ per share	(0.08)	not reported	0.04	0.22	(0.48)	not reported	(0.19)	0.32	1.16	not reported	0.94	1.90

Balance sheet

Cash and equivalents$15.2m, Q2 FY2026

Long-term debt$74.5m, Q3 FY2023

Shareholders' equity$317.5m, Q2 FY2026

Oramed Pharmaceuticals Inc., balance sheet, quarterly
Line item	Unit	Q3 FY20232023-09-30	FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Cash and equivalents	$m	not reported	9.1	18.6	10.0	not reported	54.4	not reported	15.8	52.2	45.9	13.2	15.2
Current assets	$m	176	163	177	153	143	143	131	99.0	136	133	68.2	53.4
Total assets	$m	231	221	204	184	165	155	148	162	220	231	269	370
Current liabilities	$m	78.2	53.2	33.6	3.7	5.3	5.7	5.5	3.7	6.1	19.1	10.6	10.7
Total liabilities	$m	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Long-term debt	$m	74.6	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Short-term borrowings	$m	75.4	51.0	32.0	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Shareholders' equity	$m	149	164	167	177	156	146	141	155	203	200	238	317

Cash flow

Operating cash flow−$200.0k, Q2 FY2026

Capital expenditure$2.0k, Q2 FY2026

Share repurchases$4.0m, Q4 FY2025

Oramed Pharmaceuticals Inc., cash flow, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Operating cash flow	$m	(0.7)	(1.4)	(1.5)	2.1	(7.1)	(1.9)	(3.5)	(3.5)	(1.6)	(0.5)	(2.9)	(0.2)
Capital expenditure	$m	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Dividends paid	$m	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	10.4	0.1
Share repurchases	$m	not reported	not reported	not reported	not reported	not reported	1.2	not reported	not reported	0.4	4.0	not reported	not reported

Diluted shares (weighted)42.50m, Q2 FY2026

Oramed Pharmaceuticals Inc., shares, quarterly
Line item	Unit	Q3 FY20222022-09-30	Q1 FY20232023-03-31	Q2 FY20232023-06-30	Q3 FY20232023-09-30	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Diluted shares (weighted)	m shares	39.1	40.0	40.2	40.4	41.6	41.6	40.9	41.2	42.6	42.8	42.0	42.5

Shares outstanding: 41.60m at Aug 10, 2026, from the cover of the 10-Q filed Aug 10, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:35 ET. Listed shows no prices and gives no investment advice.